_version_ 1784699701051785216
author Todeschini, A.
Contaldo, A.
Macaluso, F.S.
Facciotti, F.
Castiglione, F.
Nardone, O.M.
Spagnuolo, R.
Doldo, P.
Riguccio, G.
Conforti, F.S.
Viganò, C.
Ascolani, M.
Bodini, G.
Milla, M.
Scardino, G.
Vernero, M.
Desideri, F.
Mannino, M.
Rizzo, G.
Di Leo, A.
Orlando, A.
Principi, M.
author_facet Todeschini, A.
Contaldo, A.
Macaluso, F.S.
Facciotti, F.
Castiglione, F.
Nardone, O.M.
Spagnuolo, R.
Doldo, P.
Riguccio, G.
Conforti, F.S.
Viganò, C.
Ascolani, M.
Bodini, G.
Milla, M.
Scardino, G.
Vernero, M.
Desideri, F.
Mannino, M.
Rizzo, G.
Di Leo, A.
Orlando, A.
Principi, M.
author_sort Todeschini, A.
collection PubMed
description
format Online
Article
Text
id pubmed-9065948
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90659482022-05-04 OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD) Todeschini, A. Contaldo, A. Macaluso, F.S. Facciotti, F. Castiglione, F. Nardone, O.M. Spagnuolo, R. Doldo, P. Riguccio, G. Conforti, F.S. Viganò, C. Ascolani, M. Bodini, G. Milla, M. Scardino, G. Vernero, M. Desideri, F. Mannino, M. Rizzo, G. Di Leo, A. Orlando, A. Principi, M. Dig Liver Dis Oral Communications Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2022-05 2022-05-04 /pmc/articles/PMC9065948/ http://dx.doi.org/10.1016/S1590-8658(22)00278-X Text en © 2022 Editrice Gastroenterologica Italiana S.r.l. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Oral Communications
Todeschini, A.
Contaldo, A.
Macaluso, F.S.
Facciotti, F.
Castiglione, F.
Nardone, O.M.
Spagnuolo, R.
Doldo, P.
Riguccio, G.
Conforti, F.S.
Viganò, C.
Ascolani, M.
Bodini, G.
Milla, M.
Scardino, G.
Vernero, M.
Desideri, F.
Mannino, M.
Rizzo, G.
Di Leo, A.
Orlando, A.
Principi, M.
OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
title OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
title_full OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
title_fullStr OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
title_full_unstemmed OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
title_short OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
title_sort oc.02.1 safety of covid-19 vaccine in patients with inflammatory bowel disease: data of a national study (escape-ibd)
topic Oral Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065948/
http://dx.doi.org/10.1016/S1590-8658(22)00278-X
work_keys_str_mv AT todeschinia oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT contaldoa oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT macalusofs oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT facciottif oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT castiglionef oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT nardoneom oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT spagnuolor oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT doldop oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT rigucciog oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT confortifs oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT viganoc oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT ascolanim oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT bodinig oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT millam oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT scardinog oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT vernerom oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT desiderif oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT manninom oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT rizzog oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT dileoa oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT orlandoa oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd
AT principim oc021safetyofcovid19vaccineinpatientswithinflammatoryboweldiseasedataofanationalstudyescapeibd